Allergies News and Research

Latest Allergies News and Research

University of Missouri researchers work on immune-strengthening vaccine for newborns

As soon as babies are born, they are susceptible to diseases and infections, such as jaundice and e-coli. For up to a month, their immune systems aren't adequately developed to fight diseases. Although these infections are often minor, they can lead to serious problems if left untreated.

16 Dec 2009

Advanced Plasma Products launches its new TriClean Pro air sanitizer

Applied Science Products, Inc., announced today that its wholly owned subsidiary, Advanced Plasma Products Inc., has introduced its new TriClean Pro air sanitizer product powered by the company's newest advanced plasma generator design.

15 Dec 2009

Modified blood adult stem-cell transplant regimen reverses sickle cell disease

A modified blood adult stem-cell transplant regimen has effectively reversed sickle cell disease in 9 of 10 adults who had been severely affected by the disease, according to results of a National Institutes of Health study in the Dec. 10 issue of the New England Journal of Medicine.

13 Dec 2009

Clinical trial of 2009 H1N1 influenza vaccine

HIV-infected adults currently are being recruited to participate in a clinical trial of 2009 H1N1 influenza vaccine. The study, sponsored by the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health, will enroll approximately 240 men and women between the ages of 18 and 64.

13 Dec 2009

Circassia raises GBP15M for development of its novel allergy T-cell vaccines portfolio

Circassia Ltd, a specialty biopharmaceutical company focused on allergy, today announced that it has completed a GBP15 million ($25 million) fundraising. The investment round, which was led by Imperial Innovations and supported by existing shareholders including Invesco Perpetual and Lansdowne Partners, was significantly oversubscribed and is the company's third successful fundraising.

11 Dec 2009

Speaker Pelosi lauds lift of ban on federal funding for syringe exchange initiatives

Speaker Nancy Pelosi issued the following statement today applauding the inclusion of language in the fiscal year 2010 Consolidated Appropriations Act lifting the ban on federal funding for syringe exchange initiatives to prevent the spread of HIV. The omnibus bill passed the House this afternoon by a vote of 221 to 202.

11 Dec 2009

NIH awards $14.6M for Eukaryotic Pathogen Genome Database Resource expansion

Researchers from the University of Pennsylvania and the University of Georgia have been awarded a five-year, $14.6 million contract from the National Institute of Allergy and Infectious Diseases, part of the US National Institutes of Health, to expand and extend work on the Eukaryotic Pathogen Genome Database Resource, http://EuPathDB.org.

11 Dec 2009

Second-quarter fiscal 2010 results announced by Peregrine Pharmaceuticals

Peregrine Pharmaceuticals, Inc. today announced financial results for the second quarter of fiscal year (FY) 2010 ended October 31, 2009. Total revenue for the second quarter of FY 2010 increased 255% to $6,896,000, compared to $1,941,000 for the comparable prior year quarter.

10 Dec 2009

Knowledge gaps exist among physicians in diagnosis and management of food allergy

With an estimated four to six percent of children in the U.S. suffering from food allergies, a new study shows that pediatricians and family physicians aren't always confident they have the ability to diagnose or treat food allergies.

10 Dec 2009

Alternative, fast and safe process for producing large quantities of effective flu vaccines

A shortage of flu vaccines may soon become a problem of the past. Researcher Manon Cox has developed an alternative process for producing large quantities of safe and effective vaccines at twice to four times the usual speed. The process is based on using cells in bioreactors instead of fertilised chicken's eggs, which have a limited availability.

9 Dec 2009

Recruitment complete in Oxagen's OC000459 IIb clinical trial for asthma

Oxagen Limited, a drug discovery and development company specializing in inflammation, today announced that the recruitment for its double blind, randomised, placebo controlled Phase IIb clinical trial in asthma with OC000459, its lead oral CRTH2 (DP2) antagonist, has now been completed.

9 Dec 2009

New data provide comprehensive review of emerging role of small airways in asthma management

Teva Respiratory, a division of Teva Pharmaceutical Industries Ltd., today announced the publication of four articles in a special supplement of the December issue of the Journal of Allergy and Clinical Immunology (JACI), providing a comprehensive scientific review of the emerging role of the small airways in the understanding and treatment of asthma.

8 Dec 2009

ASH meeting highlights H1N1 pandemic threat, new trends and treatment options for children with genetic blood disorder

Sickle cell disease, a condition characterized by deformed and dysfunctional red blood cells, is one of the most common genetic blood disorders affecting millions of people around the world, including more than 70,000 Americans (National Heart, Lung, and Blood Institute.

8 Dec 2009

H1N1 virus produces pulmonary damage similar to earlier flu pandemics

In fatal cases of 2009 H1N1 influenza, the virus can damage cells throughout the respiratory airway, much like the viruses that caused the 1918 and 1957 influenza pandemics, report researchers from the National Institutes of Health (NIH) and the New York City Office of Chief Medical Examiner.

8 Dec 2009

Potentially promising data from Phase I/II study of elotuzumab presented at ASH 2009

Facet Biotech Corporation and Bristol-Myers Squibb Company announced that potentially promising data from a Phase I/II study of elotuzumab, an investigational humanized antibody being studied for the treatment of relapsed multiple myeloma (MM), were presented today at the American Society of Hematology (ASH) 2009 Annual Meeting in New Orleans.

8 Dec 2009

Prenatal exposure to microbes may help protect child from developing allergies later in life

A pregnant woman's exposure to microbes may protect her child from developing allergies later in life. Researchers in Marburg, Germany find that exposure to environmental bacteria triggers a mild inflammatory response in pregnant mice that renders their offspring resistant to allergies.

8 Dec 2009

Allergies News and Research

Latest Allergies News and Research

University of Missouri researchers work on immune-strengthening vaccine for newborns

Advanced Plasma Products launches its new TriClean Pro air sanitizer

Modified blood adult stem-cell transplant regimen reverses sickle cell disease

Clinical trial of 2009 H1N1 influenza vaccine

Circassia raises GBP15M for development of its novel allergy T-cell vaccines portfolio

Speaker Pelosi lauds lift of ban on federal funding for syringe exchange initiatives

NIH awards $14.6M for Eukaryotic Pathogen Genome Database Resource expansion

Second-quarter fiscal 2010 results announced by Peregrine Pharmaceuticals

Knowledge gaps exist among physicians in diagnosis and management of food allergy

Alternative, fast and safe process for producing large quantities of effective flu vaccines

Recruitment complete in Oxagen's OC000459 IIb clinical trial for asthma

New data provide comprehensive review of emerging role of small airways in asthma management

ASH meeting highlights H1N1 pandemic threat, new trends and treatment options for children with genetic blood disorder

H1N1 virus produces pulmonary damage similar to earlier flu pandemics

Potentially promising data from Phase I/II study of elotuzumab presented at ASH 2009

Prenatal exposure to microbes may help protect child from developing allergies later in life

La Jolla Pharmaceutical enters into definitive merger agreement with Adamis Pharmaceuticals

H1N1 virus causes more life-threatening complications than seasonal flu

Adamis Pharmaceuticals to acquire La Jolla Pharmaceutical Company

Smoking cessation offers measurable benefits for asthmatic patients

Evolving spectrophotometry for modern biopharma workflows

Scaling B-cell cloning workflows for antibody development

Fluidics in Modern Healthcare & Medical Device Innovation

Allergies News and Research

Latest Allergies News and Research

Evolving spectrophotometry for modern biopharma workflows

Scaling B-cell cloning workflows for antibody development

Fluidics in Modern Healthcare & Medical Device Innovation

Newsletters you may be interested in